¸õ¨ì¥D­n¤º®e°Ï¶ô
½Ã±Ð¸ê°T¤º®e
¼Ð¡@¡@ÃD

ºC©ÊµÇŦ¯e¯f-§ïµ½³J¥Õ§¿¤§ªvÀø

¤j¡@¡@Ãþ
¥ÎÃıШ|
±i¶K¤é´Á
2021-06-21
±i¶K³æ¦ì
Ãľ¯¬ì
¤º¡@¡@®e

ºC©ÊµÇŦ¯e¯f¡]Chronic Kidney Disease, CKD¡^¤@ª½¬O¥@¬É½Ã¥Í²Õ´©Ò­«µøªºÄ³ÃD¤§¤@¡A¥Ø«e¥þ²y²±¦æ²v¬ù8~16%¡A¤£¦P°ê®a¤£¦P°Ï°ìºC©ÊµÇŦ¯e¯fµo¥Í²v¥ç¤£¬Û¦P¡A¦Ó¦~ªø¡B°ª¦åÀ£©M¿}§¿¯fµ¥ºC©Ê¯f³£¬O³y¦¨ºC©ÊµÇŦ¯e¯f¥i¯àªº¦]¯À¡C

¥Ø«e³Q»{¬°¨ã¦³§ïµ½³J¥Õ§¿®ÄªGªºÃĪ«¡A¦³­°¦åÀ£Ãþªº¦åºÞ±i¤O¯ÀÂà¤Æ酶§í¨î¾¯¡]Angiotensin Converting Enzyme inhibitors¡AACEI¡^¤Î¦åºÞ±i¤O¯À²Ä¤G«¬¨üÅéªýÂ_¾¯¡]Angiotensin II Receptor blockers¡AARB¡^ÃĪ«¡Bpentoxifylline¡Bdipyridamole¡Bºû¥Í¯ÀDµ¥¡C¥H¤U´N³o¨ÇÃĪ«¶i¦æ»¡©ú¡C

¤@¡B¦åºÞ±i¤O¯ÀÂà¤Æ酶§í¨î¾¯(ACEI)©M¦åºÞ±i¤O¯À²Ä¤G«¬¨üÅéªýÂ_¾¯(ARB)
ACEI »PARB³o¨âÃþ­°¦åÀ£ÃĪ«³£¨ã¦³«OÅ@¤ßŦ¦åºÞ»PµÇŦªº®ÄªG¡A¤w³QÃÒ¹ê¯à¦³®Ä§ïµ½³J¥Õ§¿ªº°ÝÃD¡A¯S§O¬O¦b¿}§¿¯f¯f¤H¨­¤W¡A§ó¯àµo´§¨ä³Ì¨ÎÁ{§É®Ä¯q¡A¹F¨ì©µ½wµÇ¥\¯à¤U­°ªº®ÄªG¡C¥D­n­ì¦]¬O¸ÓÃþÃĪ«§í¨îµÇ¯À-¦åºÞ±i¤O¯À-îÇ©Tନt²Î¡]Renin-Angiotensin-Aldosterone System; RAAS¡^¡A¦b¤£¼vÅT¥þ¨­©Ê¦åÀ£±¡ªp¤U¡A¦P®ÉÂX±i¥X²y¤Î¤J²y¤p°Ê¯ß¡A¦]¦Ó§ó¯à¦³®Ä­°§CµÇµ·²yªºÀ£¤O¡A¹F¨ì´î¤Ö³J¥Õ§¿¤§®ÄªG¡C¦]¦¹¡A¹ï©ó«D°ª¦åÀ£¦ý¦³©úÅã³J¥Õ§¿¤§¯f¤H¦Ó¨¥¡A¥i¨Ï¥Î¦¹ÃþÃĪ«§@¬°§ïµ½³J¥Õ§¿¤§ªvÀø¡C®Ú¾ÚKDIGO¡]The Kidney Disease: Improving Global Outcomes organization¡^«ü«n«ü¥X¡A¹ïºC©ÊµÇŦ¯e¯f¯f¤H¦Ó¨¥¡AµL½×¬O§_¿©±w¿}§¿¯f¡A¨C¤é§¿²G¤¤¥Õ³J¥Õ±Æ¥X¶q¤j©ó300 mgªÌ¡A«ØÄ³¥i¨Ï¥ÎACEI©ÎARBÃþÃĪ«¶i¦æªvÀø¡C¨Ï¥Î¦¹ÃþÃĪ«ªvÀøªì´Á¡A¥i¯àµo¥Í¦å²M¦Ù»ÄÓþ¼W¥[ªº±¡§Î¡A¥D­n­ì¦]¥i¯à©MµÇµ·²y·L¦åºÞ¤ºÀ£¤Oµo¥ÍÅܤƦ³Ãö¡CÃĪ«§í¨îµÇ¯À-¦åºÞ±i¤O¯À-îÇ©Tନt²Î¡A­°§CµÇµ·²y·L¦åºÞ¤ºÀ£¤O¡A³y¦¨µÇµ·²y¹LÂo³t²v¦b¥ÎÃÄ«e´Á¦³¤U­°ªº±¡§Î¡A¦]¦Ó³y¦¨¦å²M¦Ù»ÄÓþ¤W¤É¡CÁöµM¦p¦¹¡A¥ç¤£«ØÄ³¦]¦Ó°±¥ÎACEI©ÎARB¡A¤@¯ë»{¬°ªvÀøªì´Á«e2~4­Ó¤ë´Á¶¡¡A¦å²M¦Ù»ÄÓþ¼W¥[ªº´T«×¦b¥¿±`­Èªº30~35%¤§¤º¡A¬O¥i³Q±µ¨üªº¦X²z½d³ò¡C
§í¨îµÇ¯À¡V¦åºÞ±i¤O¯À¡V¥Ö½èîÇନt²Î¥i¯àµo¥Í¤@¨Ç¤£¨}§@¥Î¡C¨Ò¦p°ª¦å¹[¡A¬OªvÀø´Á¶¡À³¯S§O¯d·NªºÃĪ«¤£¨}¤ÏÀ³¡Aí©w¥B¥i±±¨îªº°ª¦å¹[¯g¨Ã¤£»Ý¥ß§Y°±¤îACEI©ÎARBªvÀø¡C¦Ó¨Ï¥ÎACEI©ÎARB³£¥i¯à¾É­PµÇµ·²y¹LÂo²v¤U­°¡A¤×¨ä¦bÅé²G¤£¨¬¡BµÇ°Ê¯ß¦åºÞ¯U¯¶©Î¤ßŦ°IºÜªº¯f¤H¨­¤W¡A¦pªGµÇµ·²y¹LÂo²v­°´T¡Õ20% ¥BÁÍ©óí©w¡A¤@¯ë¨Ã¤£»Ý¥ß§Y°±¤îACEI ©ÎARB¡C
¥Ø«e¥xÆW¤W¥«ªºACEI¥]¬A¡Gcaptopril¡Benalapril¡Bimidapril¡Bfosinopril¡Bperindopril¡Bramiprilµ¥¡FARB ¥]¬A¡GAzilsartan¡Bcandesartan¡Birbesartan¡Blosartan¡Bolmesartan¡Btelmisartan¡Bvalsartanµ¥¡C

¤G¡BPENTOXIFYLLINE
Pentoxifylline¬Omethylxanthineªº­l¥Íª«¡A¦³¼W¥[©PÃä·L¦åºÞÄé¬yªº§@¥Î¡A¤@¯ë¥Î©ó§ïµ½¥½±é¦åºÞ´`Àô»Ùꪺ°ÝÃD¡C¦¹¥~¡A¥¦¤]¯à§í¨îÁC»Ä¤Gà­酶¡A¨ã¦³§Üµoª¢¡B§ÜÅÖºû¤Æ¤Î§í¨î²Ó­M¼W¥Íªº¯S©Ê¡C¦]¦¹¡A³Q»{¬°¹ïºC©ÊµÇŦ¯e¯f¯f¤HµÇ¥\¯àªººû«ù¥i¯à¨ã¦³¤@©wªºÀ°¦£¡C®Ú¾ÚÁ{§É¬ã¨s«ü¥X¡A±w¦³²Ä¤G«¬¿}§¿¯fªº¯f¤H¡A¨Ï¥ÎACEI/ARB¥[¤WpentoxifyllineªºªvÀø¡A¬Û¸û©ó³æ¥ÎACEI/ARBªvÀøªÌ¡A¨ä³J¥Õ§¿ªº§ïµ½®ÄªG§ó¨Î¡CµM¦Ó¡A¥Ø«e¬ÛÃö¬ã¨s¤j¦hÄÝ©ó¸û¤p«¬ªº¸ÕÅç¡A¥çµLªkÃÒ¹êpentoxifylline¹ïµÇŦªºªø´Á¼vÅT¡A©|¶·¶i¤@¨Bªº¬ã¨s¨Ó±´°Q¨äÀø®Ä¡C

¤T¡BDIPYRIDAMOLE
¬O¤@­Ó®Ö苷¹B°eªº§í¨î¾¯¡A¤]¬O¤@­Ó«D¿ï¾Ü©ÊÁC»Ä¤Gà­酶ªº§í¨î¾¯¡C¨ã¦³§Üµoª¢¤Î§Ü®ñ¤Æªº§@¥Î¡AÁ{§É¤W¦³¥Î¨Ó§ïµ½³J¥Õ尿¡C¦³¬ã¨sÅã¥ÜDIPYRIDAMOLE¯à­°§C³J¥Õ§¿¨Ã§ïµ½µÇ¥\¯à´c¤Æªº¶iµ{¡A¯S§O¬O¦b¦­´ÁºC©ÊµÇŦ¯e¯fªºµÇµ·²y¯fÅܯf¤H¡C¨Ï¥ÎDIPYRIDAMOLE¦b­°§C¥½´ÁµÇŦ¯e¯f¤Î¦º¤`²vªº­·ÀI¤]¦³ÃöÁp©Ê¡C¥Ø«e¤j¦hÄÝ©ó¤p«¬ªº¬ã¨s¡A»Ý­n¶i¤@¨Bªº¬ã¨s¨Ó±´°Q¹ïµÇŦ¥¿­±ªº¦n³B¡C

¥|¡Bºû¥Í¯ÀD
ºû¥Í¯ÀD¬O¤@ºØ¯×·»©Êºû¥Í¯À¡A¬°¤HÅ饲»ÝÀç¾i¯À¤§¤@¡Fºû¥Í¯ÀD¬O©Ò¦³¨ãcholecalciferol ¤§¥Íª«¬¡©Ê©T¾JÃþª«½èªº²ÎºÙ¡A¥D­n§@¥Î¬°«P¶i¸z­G§l¦¬¶t©MÁC¡Cºû¥Í¯ÀD ¦³«Ü¦hºØ§Î¦¡¡A³Ì±`¨£ªº¬O³Á¨¤¶t¾J¡]ergocalciferol, vitamin D2¡^»PÁx¶t¾J¡]cholecalciferol, vitamin D3¡^¡C
¬¡¤Æºû¥Í¯ÀD¨üÅé¡]vitamin D receptor¡AVDR¡^¡A³Q»{¬°¹ïµÇµ·²y¨¬²Ó­M¡]podocyte¡^¨ã¦³«OÅ@§@¥Î¡A¨¬²Ó­M¬OµÇµ·²y¹LÂo¼h²Õ¦¨¤§¤@¡A¦bµÇµ·²y¹LÂo§@¥Î¤¤¡A§êºt­«­nªº¨¤¦â¡A¦P®É¤]©M³J¥Õ§¿ªºµo¥Í¨ã¦³ÃöÁp©Ê¡F°£¦¹¤§¥~¡A¥¦¤]·|´î½wµÇ¯À-¦åºÞ±i¤O¯À-îÇ©Tନt²Îªº¬¡¤Æ¡A¨ã¦³§Üµoª¢¤Î§ÜÅÖºû¤Æªº§@¥Î¡A³o¨Ç³£¬Oºû¥L©RDÃþ¦üª«¥i¯à¨ã¦³´î¤Ö³J¥Õ§¿¥\®Äªº­ì¦]¡C

¤­¡B¬¡©ÊºÒ¡]§Jùجü²b¡^
AST-120¡]Kremezin®¡^¬O¤@ª½®|0.2-0.4 mm²y§Î¬¡©ÊºÒ¡Aªí­±¤W¦³³\¦h·L¤p¤Õ¡A§Î¦¨¼s¤j§lªþ­±¿n¡A¥i¥H§lªþ»Ä©Ê©MÆP©Ê¦³¾÷¤Æ¦Xª«¡F¹ï©ó¥]§t§¿¬r¯À¤p¤À¤l¦³·¥±jªº§lªþ¤O¡A¹ï©ó¥]§t®ø¤Æ酶ªº¤j¤À¤l§lªþ¤O´N¤ñ¸û§C¡A¥xÆW¥]¸Ë¬O¤@¥]2 gm¡C¥Ø«eÂå¬É¹ï¦¹¨ÃµL¤@­Pµ²½×¡A¬ã¨sÅã¥Ü¡A¦­´ÁµÇŦ¯f¤H¨Ï¥ÎAST-120 ©µ½wµÇµ·²y¹LÂo²v¤U­°ªº´T«×¦ü¥G®ÄªG¸û¦n¡C

¤»¡BSTATINs
Statins¬°HMG-CoAÁÙ­ì酶§í¨î¾¯(HMG-CoA reductase inhibitors)¡A¬O¤@Ãþ­°¦å¯×ÃĪ«¡C¬ã¨s»{¬°statins¹ï©óµÇµ·²y¨¬²Ó­M¨ã¦³«OÅ@§@¥Î¡A¤]¦³§ïµ½¤º¥Ö¥\¯à»Ùê¡B¹w¨¾µÇµ·²y¶¡½è·l¶Ëªº¥\®Ä¡A¦]¦¹¯à­°§C³J¥Õ§¿ªº±¡§Î¡CµM¦Ó¤]¦³¬ã¨s«ü¥X¡A¨Ã«D©Ò¦³statins³£¨ã¦³§ïµ½³J¥Õ§¿ªº®ÄªG¡AStatins¹ï©óºC©ÊµÇŦ¯e¯f¯f¤H³J¥Õ§¿ªº¼vÅT¡A¤´»Ý§ó¦hªº¬ÛÃö¬ã¨s±´°Q¡C
¥Ø«e¥xÆW¤W¥«ªºstatins ¥]¬A¡Aatorvastatin¡Bfluvastatin lovastatin¡Bpitavastatin¡Bpravastatin¡Brosuvastatin¡Bsimvastatinµ¥¡C

µ²½×
¥Ø«e°w¹ï³J¥Õ§¿ªºªvÀø¡A¤´¥HACEI¤ÎARBÃþÃĪ«¬°³Ì¨ã¥D­n¤§ªvÀøÃĪ«¡A¨ä¥LÃþÃĪ««h¦³¸û¤p«¬¬ã¨sÃҹ굲ªG¡A¦ý¤´»Ý§ó¦h¸ÕÅç¶i¦æ§óªø»·¤§ºÊ´ú¡C¦¹¥~¡A°£ÃĪ«ªvÀø¥~¡A¥Í¬¡¶¼­¹±±¨î¡A¤]¹ï§ïµ½³J¥Õ§¿¨ã¦³¤@©wªº§@¥Î¡C´î¤Ö¶uÆQÄá¨ú¡A±±¨î¨C¤éÄá¨ú¶q<2g¡Aºû«ù¨­Åé½è¶q«ü¼Æ(BMI)­È¦b¼Ð·Ç½d³ò 20~25 kg/m2¶¡¡B§ÙµÒ¡B¨C©P«ùÄò¹B°Ê¦Ü¤Ö5¦¸¡A¨C¦¸¹B°Ê30¤ÀÄÁµ¥µ¥¡A³£¯à¹F¨ì´î¤Ö³J¥Õ§¿ªº§@¥Î¡C°£¦¹¤§¥~¡A§ïµ½¥»¨­¯e¯fª¬ªp¡A¨Ò¦p¿}§¿¯f¯f±w­Y¯à¦³®Ä±±¨î¦å¿}¡Aºû«ùHbA1C¼Æ­È< 7%¡A¤]¬O´î¤Ö³J¥Õ§¿ªº­«­n¦]¯À¡C

¸ê®Æ¨Ó·½¡G
1.ÃÄ®v¶g¥Z²Ä2022-2024´Á
2.2015¥xÆWºC©ÊµÇŦ¯fÁ{§É¶EÀø«ü¤Þ
3.Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. Kaohsiung J Med Sci. 2014 Dec;30(12):599-607.

¦^ÂsÄý­¶
¥»°|¬°µLµÒÂå°|,¥þ­±¸T¤î§lµÒ
ÂsÄý¤H¼Æ
24820018
¥Ø«e½u¤W¤H¼Æ¡G¤H
³Ì«á§ó·s:2022-06-25
¥»ºô¯¸¤º®e©Ò¦³ÅvÂk½Ã¥ÍºÖ§Q³¡»O¤¤Âå°|©Ò¦³¡A¸T¤î¥ô·NÂà¸ü¡B½Æ»s©Î°µ°Ó·~¥Î³~
(¦ý¥Hºô¸ô·j´M©Î¶W³sµ²¤è¦¡¡A¶i¤JÂåÀø¾÷ºc¤§ºô§}¡]°ì¡^ª½±µÂI¾\ªÌ¡A¤£¦b¦¹­­)
¥»ºô¯¸«ØÄ³¨Ï¥ÎIE10.0¥H¤WÂsÄý¾¹¡A³Ì¨Î¸ÑªR«×¬°1920¡Ñ948